Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambridge Cognition HoldingsLSE:COG 37 3-Year EPS without NRI Growth Rate is -135.10% as of Jun. 2026. GuruFocus rates LSE:COG with a GF Score™ of 37/100 and a GF Value™ of £0.32 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 503 Healthcare Providers & Services companies, Cambridge Cognition Holdings ranks worse than 98.61% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was -135.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Cambridge Cognition Holdings was 71.10% per year. The lowest was -135.10% per year. And the median was -6.30% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Cambridge Cognition Holdings 3-Year EPS without NRI Growth Rate Related Terms
LSE:COG vs VEEV, BTSG, TEM: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Cambridge Cognition Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Cognition Holdings 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cambridge Cognition Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Cambridge Cognition Holdings's 3-Year EPS without NRI Growth Rate falls into.
Cambridge Cognition Holdings 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -135.10% mean?
Cambridge Cognition Holdings (LSE:COG) has a 3-Year EPS without NRI Growth Rate of -135.10% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cambridge Cognition Holdings and its competitors. According to the industry distribution chart, Cambridge Cognition Holdings ranks #496 out of 503 companies in the Healthcare Providers & Services industry, placing it in the top 98.6%.
Is Cambridge Cognition Holdings' 3-Year EPS without NRI Growth Rate too high?
Cambridge Cognition Holdings' current 3-Year EPS without NRI Growth Rate is -135.10%. Based on the distribution chart, Cambridge Cognition Holdings ranks #496 out of 503 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cambridge Cognition Holdings has a GF Score™ of 37/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cambridge Cognition Holdings' 3-Year EPS without NRI Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cambridge Cognition Holdings ranks #496 out of 503 companies for 3-Year EPS without NRI Growth Rate. This places Cambridge Cognition Holdings in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.00, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cambridge Cognition Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Cognition Holdings's current 3-Year EPS without NRI Growth Rate is -135.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Cognition Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Cognition Holdings (LSE:COG) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.32, compared to a current price of £0.28 — trading 14.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -135.10%. Cambridge Cognition Holdings' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Cambridge Cognition Holdings (LSE:COG), the current 3-Year EPS without NRI Growth Rate is -135.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cambridge Cognition Holdings (LSE:COG) Overvalued in 2026?
Based on GuruFocus' analysis, Cambridge Cognition Holdings stock appears to be undervalued.
The current stock price of £0.28 is trading 14.1% below its estimated GF Value™ of £0.32.
GuruFocus considers Cambridge Cognition Holdings to be Modestly Undervalued.
Key valuation signals for LSE:COG:
3-Year EPS without NRI Growth Rate: -135.10%
GF Value™: £0.32 vs. price of £0.28 (14.1% below fair value)
No single metric tells the full story. See the LSE:COG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the measurement of clinical outcomes in neurological disorders. It develops and commercialises neuroscience technologies to assess cognitive function for sale across the world. The company's products include CANTAB web-based assessments, Electronic questionnaires and scales (eCOA), NeuroVocalix Winterlight, a voice analysis tool to assess cognitive changes, high-frequency testing kits, and Clinpal, among others. Its operating segments are: Clinical studies, which generate maximum revenue, Academic research, Professional Healthcare, and Consumer Health & Wellness. Geographically, the company generates maximum revenue from the USA, and the rest from the UK, the European Union, and the Rest of the world.
37GF Score
Get the complete analysis for LSE:COG
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:COG has been successfully added to your 
